IMC-001

DRUG4 trials

Sponsors

ImmuneOncia Therapeutics Inc., Asan Medical Center

Conditions

Extranodal NK/T-cell LymphomaExtranodal NK/T-cell Lymphoma, Nasal TypeHistologically or Cytologically Proven Metastatic or Locally Advanced Solid TumorsLocally AdvancedMetastasisSolid TumorSubjects With Resectable Esophageal Cancer or Liver CancerSubjects With Resectable Liver Cancer

Phase 1

Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors

CompletedNCT03644056

ImmuneOncia Therapeutics Inc.Locally Advanced, Metastasis, Solid Tumor

Start: 2018-03-22End: 2020-05-14Updated: 2020-05-28

Phase 2

Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers

Active, not recruitingNCT04196465

Asan Medical CenterSubjects With Resectable and Localized Gastric Cancer, Subjects With Resectable Esophageal Cancer or Liver Cancer, Subjects With Resectable Liver Cancer

Start: 2019-09-09End: 2026-09-26Target: 48Updated: 2026-05-22

A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

Active, not recruitingNCT04414163

ImmuneOncia Therapeutics Inc.Extranodal NK/T-cell Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type

Start: 2020-10-27End: 2027-02-28Updated: 2026-04-24

A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor

RecruitingNCT06365840

ImmuneOncia Therapeutics Inc.Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors, TMB-H

Start: 2025-01-13End: 2029-08-01Target: 30Updated: 2026-04-17

Related Papers

Danburstotug, an anti‐ PD ‐ L1 antibody, in relapsed/refractory extra‐nodal natural killer/T‐cell lymphoma: The phase 2 DISTINKT study

British Journal of Haematology2026-08-18

Neoadjuvant Danburstotug (IMC-001) therapy in gastric, esophageal, and hepatocellular carcinoma: the NeoChance phase II study

npj Precision Oncology2026-07-03

Phase 2 study to investigate the efficacy and safety of IMC‐001, anti‐PD‐L1 antibody, in patients with relapsed or refractory extranodal NK/T cell lymphoma, nasal type: DISTINKT Study

Hematological Oncology2023-06-01

A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors.

2021-07-161 citations

Preliminary results of a phase II study of neoadjuvant immune checkpoint inhibitor IMC-001 (anti-PD-L1 monoclonal antibody) in patients with resectable gastrointestinal cancers (NeoChance Study).

Journal of Clinical Oncology2020-05-202 citations